Sinusitis Drugs Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Sinusitis Drugs Market Report is Segmented by Disease Type (Acute Sinusitis and More), Drug Class (Antibiotics, Corticosteroids, and More), Dosage Form (Tablets & Capsules and More), Prescription Status (Prescription and OTC), Patient Age Group (Pediatrics and More), Distribution Channel (Hospital Pharmacies and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Sinusitis Drugs Market Size and Share

Sinusitis Drugs Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Sinusitis Drugs Market Analysis by Mordor Intelligence

The Sinusitis Drugs Market size is projected to be USD 2.35 billion in 2026, USD 2.49 billion in 2027, and reach USD 3.49 billion by 2032, growing at a CAGR of 6.99% from 2027 to 2032.

The sinusitis drugs market is moving away from a model centered on frequent antibiotic treatment for uncomplicated acute disease. The American Academy of Otolaryngology-Head and Neck Surgery guideline supports watchful waiting for uncomplicated acute bacterial rhinosinusitis, which narrows antibiotic use while preserving treatment for clinically appropriate cases. Higher-cost biologics are becoming more important in chronic disease because they address patients with persistent symptoms and nasal polyps. The sinusitis drugs market also benefits from closer links between allergy care and ENT practice, as clinicians increasingly consider inflammatory characteristics when selecting therapy. Delivery devices, specialist access, and reimbursement decisions will shape which products convert clinical demand into sales.

Key Report Takeaways

  • By disease type, CRSwNP held 33.32% of the sinusitis drugs market share in 2026, while allergic fungal rhinosinusitis is forecast to grow at a 7.61% CAGR through 2032.
  • By drug class, antibiotics held 34.24% of the sinusitis drugs market share in 2026, while biologics are projected to grow at a 14.21% CAGR through 2032.
  • By dosage form, tablets and capsules held 39.42% of the sinusitis drugs market share in 2026, while injectable biologics are projected to grow at a 13.52% CAGR through 2032.
  • By prescription status, prescription-only medicines held 68.36% of the sinusitis drugs market share in 2026 and are projected to grow at a 6.91% CAGR through 2032.
  • By patient age group, adult patients held 63.13% of the sinusitis drugs market share in 2026, while geriatric patients are forecast to grow at a 7.41% CAGR through 2032.
  • By distribution channel, retail pharmacies held 43.31% of the sinusitis drugs market share in 2026, while online pharmacies are forecast to grow at a 9.81% CAGR through 2032.
  • By geography, North America held 41.23% of the sinusitis drugs market share in 2026, while Asia-Pacific is forecast to grow at an 8.02% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Sinusitis Drugs Market Segment Analysis

By Disease Type:

CRSwNP Anchors Value as AFRS Gains Prescription Momentum

CRSwNP accounted for 33.32% of the sinusitis drugs market share in 2026, supported by repeat prescribing and biologic use. Its treatment pathway often includes corticosteroids, surgery assessment, and escalation for patients with uncontrolled disease. Dupilumab became the first FDA-approved medicine for allergic fungal rhinosinusitis in February 2026. The approval expanded treatment beyond surgery and extended corticosteroid courses for this patient group. Allergic fungal rhinosinusitis is projected to grow at a 7.61% CAGR through 2032. This reflects both the new labeled option and the need for sustained management in a disease with inflammatory features.

Acute sinusitis maintains a large base of medicine use because episodes are frequent and often present in primary care. Guideline recommendations are shifting uncomplicated cases toward symptomatic care and observation when clinically appropriate

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Sinusitis Drugs Market Share by Disease Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Sinusitis Drugs Market Share by Disease Type, 2026

By Drug Class:

Antibiotics Defend Revenue Share Amid Structural Headwinds

Antibiotics held 34.24% of the sinusitis drugs market share in 2026 because acute and subacute episodes still generate substantial prescription frequency. Their position is reinforced by familiar use patterns in front-line care. The 2025 AAO-HNS guideline has narrowed prescribing toward amoxicillin with or without clavulanate for indicated cases. This constrains product differentiation among broader-spectrum competitors. The category remains large but faces lower volume growth as stewardship becomes more embedded. Manufacturers therefore need support from adjacent therapeutic classes to offset this pressure.

Biologics are expected to expand at a 14.21% CAGR through 2032, the strongest rate among drug classes. They address severe CRSwNP and related inflammatory disease where standard therapy has not controlled symptoms. GSK launched Exdensur, depemokimab, in Japan in April 2026 for severe asthma and CRSwNP

By Dosage Form:

Tablets Lead Share but Injectables Define Value Growth

Tablets and capsules accounted for 39.42% of the sinusitis drugs market size in 2026 because antibiotics, antihistamines, and analgesics are widely used in oral form. Oral therapies are familiar to patients and suit short treatment courses. They also serve broad acute and allergy-related demand across community settings. Injectable biologics are forecast to grow at a 13.52% CAGR through 2032. Their expansion reflects increasing use in chronic inflammatory disease and the need for specialist-directed therapy. Longer dosing intervals may improve the practical fit of injectables for patients managing recurring symptoms.

Nasal sprays remain commercially important because they deliver corticosteroids, antihistamines, and decongestants directly to the nasal passage. Exhalation-based devices can improve access to upper sinonasal areas compared with standard spray formats 

Segment this market the way your business does.

Get tailored market insights for your requirements.

Sinusitis Drugs Market Share by Dosage Form, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Sinusitis Drugs Market Share by Dosage Form, 2026

By Prescription Status:

Prescription Volumes Anchor Revenue Amid OTC Channel Expansion

Prescription-only medicines held 68.36% of the sinusitis drugs market share in 2026, reflecting the importance of biologics, branded intranasal corticosteroids, and prescription antibiotics. Their share is structural because the highest-cost therapies require clinical assessment and follow-up. Prescription revenue is forecast to grow at a 6.91% CAGR through 2032. New biologics for CRSwNP and allergic fungal rhinosinusitis will support this position. Payer requirements will remain important in determining actual treatment access. Specialist involvement also makes the prescription channel central for severe chronic disease.

By Patient Age Group:

Adult Patients Drive Volume, Geriatric Demand Accelerates

Adult patients accounted for 63.13% of the sinusitis drugs market share in 2026 because they use the broadest range of prescription and nonprescription therapies. Acute bacterial sinusitis and chronic inflammatory rhinosinusitis both create demand in this group. Adults may move from occasional over-the-counter treatment to specialist-managed biologics when disease becomes persistent. Their spending profile therefore covers the full formulary. Adult demand is also supported by work and lifestyle pressures that can favor prompt symptom management.

Geriatric patients are forecast to grow at a 7.41% CAGR through 2032 as population aging increases care needs. Polypharmacy, asthma, COPD, and immune changes can complicate treatment selection in older adults. Systemic corticosteroids and antihistamines require careful use because of recognized adverse-effect concerns. This can favor locally acting intranasal therapies and delivery formats that limit systemic exposure.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Sinusitis Drugs Market Share by Patient Age Group, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Sinusitis Drugs Market Share by Patient Age Group, 2026

By Distribution Channel:

Retail Pharmacies Lead, Online Channels Surge

Retail pharmacies accounted for 43.31% of the sinusitis drugs market share in 2026, supported by walk-in purchases of over-the-counter products. Acute congestion and facial pressure can prompt patients to seek treatment without waiting for delivery. This behavior supports retail pharmacy sales for short-duration symptom relief. Pharmacists also provide a practical point of contact for product selection and referral. The channel remains especially relevant for decongestants, saline products, and allergy medicines. It will continue to be a major route even as digital purchasing grows.

Online pharmacies are forecast to expand at a 9.81% CAGR through 2032. E-prescriptions, telepharmacy, and home delivery may improve access for older adults and patients with mobility limits. The channel is also suited to repeat orders for chronic medications and allergy products. Cold-chain handling and reimbursement workflows remain important for specialty medicines.

Geography Analysis

North America

North America held 41.23% of the sinusitis drugs market share in 2026, supported by specialist access, private insurance coverage, and biologic availability. The FDA approved tezepelumab for CRSwNP in October 2025. The agency also approved dupilumab for allergic fungal rhinosinusitis in February 2026. These approvals extend labeled treatment to patient groups previously lacking a specific medicine. The AAO-HNS guideline is also an important regulatory influence on antibiotic use in uncomplicated acute disease. This combination favors premium chronic-care therapies while moderating antibiotic volume. Manufacturers with broad labels and payer evidence have a clearer position in this setting.

Asia-Pacific

The Asia-Pacific sinusitis drugs market is projected to grow at an 8.02% CAGR through 2032. Urban pollution, aeroallergen exposure, and developing ENT infrastructure support demand across China, India, Japan, and South Korea. Japan has become a notable biologics setting because its regulatory system has approved several advanced options. GSK launched Exdensur for severe asthma and CRSwNP in Japan in April 2026. An extended dosing interval can be meaningful in an aging population that may benefit from lower treatment frequency. Domestic biologic development in China is also becoming more relevant to the regional competitive setting. Regional progress will depend on affordability, specialist capacity, and the pace of regulatory review.

Europe, Middle East and Africa, South America

Europe is shaped by EPOS guidance, which provides a common clinical framework for rhinosinusitis care. The sinusitis drugs market size across this broader group depends on different reimbursement systems and access conditions. Germany has a mature over-the-counter nasal treatment environment, while biologic access is more sensitive to payer decisions. Europe also provides an opening for biosimilars to place pricing pressure on reference biologics. In South America, Brazil has an established pharmaceutical approval framework through ANVISA. Middle East markets are developing reimbursement support, particularly in the UAE and Saudi Arabia, where allergic rhinitis can add to demand for sinonasal treatment. Across these mixed geographies, companies need country-specific pricing, evidence, and distribution plans rather than a single regional approach.

Sinusitis Drugs Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Sinusitis Drugs Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The sinusitis drugs market has two different competitive settings. Biologics are concentrated among Sanofi and Regeneron, Amgen and AstraZeneca, GSK, and Merck. Generic and over-the-counter products remain fragmented across antibiotics, antihistamines, corticosteroids, and decongestants. Sanofi reported that Dupixent outperformed Xolair on the reported primary and secondary CRSwNP endpoints in the EVEREST study. This type of comparative evidence can affect formulary decisions and physician preference. Label breadth is another practical source of differentiation in chronic inflammatory disease.

Amgen and AstraZeneca broadened the TSLP pathway with the FDA approval of Tezspire for CRSwNP in October 2025. Sanofi and Regeneron then expanded Dupixent into allergic fungal rhinosinusitis in February 2026. GSK entered the Japanese CRSwNP setting with Exdensur and its 26-week dosing interval. These actions show that companies are competing through new indications, dosing convenience, and evidence. Delivery technology is a separate area of competition because local deposition can distinguish nasal products. Aptar Pharma and Dianosic are developing a resorbable intranasal scaffold for sustained local administration.

Sinusitis Drugs Industry Leaders

  1. GSK plc

  2. Sanofi

  3. AstraZeneca

  4. Novartis AG

  5. Pfizer Inc.

  6. *Disclaimer: Major Players sorted in no particular order

Sinusitis Drugs Market Companies Covered in this Report

  • Amgen
  • Amneal Pharmaceuticals
  • AstraZeneca
  • Aurobindo Pharma
  • Bayer
  • Cipla
  • Dr. Reddy’s Laboratories
  • GlaxoSmithKline
  • Hikma Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Novartis
  • Optinose, Inc.
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sanofi
  • Sun Pharmaceuticals Industries
  • Teva Pharmaceutical Industries
  • Viatris

Recent Industry Developments in Sinusitis Drugs Market

  • April 2026: GSK launched Exdensur, depemokimab, in Japan for CRSwNP and severe asthma, the first biologic offering a 26-week dosing interval for CRSwNP, bringing the total number of approved CRSwNP biologics in Japan to 4 and intensifying competition in the country's premium ENT therapy segment.
  • February 2026: The US FDA approved Sanofi and Regeneron's Dupixent, dupilumab, for adults and children aged 6 and older with allergic fungal rhinosinusitis, the first medicine approved for this indication, based on the LIBERTY-AFRS-AIMS study demonstrating a 50% sinus opacification improvement and a 92% reduction in the risk of systemic corticosteroid use or surgery versus placebo, converting a sub-segment previously managed only surgically into an active pharmaceutical market.

Table of Contents for Sinusitis Drugs Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic and Acute Rhinosinusitis
    • 4.2.2 Expanding Biologic Use in Severe CRSwNP
    • 4.2.3 Growth in Intranasal Drug-Delivery Innovation
    • 4.2.4 Increased Diagnosis of Allergy-Associated Sinus Disease
    • 4.2.5 Clinician Adoption of Phenotype-Directed Therapy
    • 4.2.6 Digital ENT Triage and Remote Treatment Monitoring
  • 4.3 Market Restraints
    • 4.3.1 Antibiotic Stewardship and Resistance Concerns
    • 4.3.2 High Cost and Reimbursement Restrictions for Biologics
    • 4.3.3 Limited Predictive Biomarkers for Treatment Selection
    • 4.3.4 Persistent Underdiagnosis and ENT Workforce Shortages
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Industry Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Disease Type
    • 5.1.1 Acute Sinusitis
    • 5.1.2 Subacute Sinusitis
    • 5.1.3 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 5.1.4 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
    • 5.1.5 Allergic Fungal Rhinosinusitis
    • 5.1.6 Other Sinusitis Types
  • 5.2 By Drug Class
    • 5.2.1 Antibiotics
    • 5.2.2 Corticosteroids
    • 5.2.3 Antihistamines
    • 5.2.4 Decongestants
    • 5.2.5 Analgesics & Pain Relievers
    • 5.2.6 Biologic Therapies
    • 5.2.7 Other Drug Classes
  • 5.3 By Dosage Form
    • 5.3.1 Tablets & Capsules
    • 5.3.2 Nasal Sprays
    • 5.3.3 Nasal Drops
    • 5.3.4 Syrups & Liquids
    • 5.3.5 Injectable Biologics
    • 5.3.6 Other Dosage Forms
  • 5.4 By Prescription Status
    • 5.4.1 Prescription-Only Medicines
    • 5.4.2 Over-the-Counter Medicines
  • 5.5 By Patient Age Group
    • 5.5.1 Pediatric Patients
    • 5.5.2 Adult Patients
    • 5.5.3 Geriatric Patients
  • 5.6 By Distribution Channel
    • 5.6.1 Hospital Pharmacies
    • 5.6.2 Retail Pharmacies
    • 5.6.3 Online Pharmacies
    • 5.6.4 Other Distribution Channels
  • 5.7 By Geography
    • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
    • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 India
    • 5.7.3.3 Japan
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
    • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
    • 6.3.1 Amgen Inc.
    • 6.3.2 Amneal Pharmaceuticals, Inc.
    • 6.3.3 AstraZeneca
    • 6.3.4 Aurobindo Pharma Limited
    • 6.3.5 Bayer AG
    • 6.3.6 Cipla Limited
    • 6.3.7 Dr. Reddy's Laboratories Ltd.
    • 6.3.8 GSK plc
    • 6.3.9 Hikma Pharmaceuticals PLC
    • 6.3.10 Johnson & Johnson
    • 6.3.11 Merck & Co., Inc.
    • 6.3.12 Novartis AG
    • 6.3.13 Optinose, Inc.
    • 6.3.14 Pfizer Inc.
    • 6.3.15 Regeneron Pharmaceuticals, Inc.
    • 6.3.16 Sanofi
    • 6.3.17 Sun Pharmaceutical Industries Ltd.
    • 6.3.18 Teva Pharmaceutical Industries Ltd.
    • 6.3.19 Viatris Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & unmet-need assessment

Global Sinusitis Drugs Market Report Scope

The sinusitis drugs market comprises pharmaceutical products used for the treatment and management of acute and chronic sinusitis, including inflammatory, infectious, allergic, and polyp-associated sinonasal disorders.

The market is segmented by disease type into acute sinusitis, subacute sinusitis, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), allergic fungal rhinosinusitis, and other sinusitis types. Based on drug class, the market includes antibiotics, corticosteroids, antihistamines, decongestants, analgesics and pain relievers, immunotherapy drugs, biologic therapies, and other drug classes such as saline nasal sprays, irrigation products, and antifungal agents.

Based on dosage form, the market is categorized into tablets and capsules, nasal sprays, nasal drops, syrups and liquids, injectable biologics, and other dosage forms. By prescription status, the market is segmented into prescription-only medicines and over-the-counter medicines. The market is further segmented by patient age group into pediatric patients, adult patients, and geriatric patients. Based on distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

Geographically, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. For each segment, the market size and forecast are provided in terms of value (USD).

Segmentation Overview

By Disease Type
Sinusitis Drugs Market segmentation breakdown
Acute Sinusitis
Subacute Sinusitis
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
Allergic Fungal Rhinosinusitis
Other Sinusitis Types
By Drug Class
Sinusitis Drugs Market segmentation breakdown
Antibiotics
Corticosteroids
Antihistamines
Decongestants
Analgesics & Pain Relievers
Biologic Therapies
Other Drug Classes
By Dosage Form
Sinusitis Drugs Market segmentation breakdown
Tablets & Capsules
Nasal Sprays
Nasal Drops
Syrups & Liquids
Injectable Biologics
Other Dosage Forms
By Prescription Status
Sinusitis Drugs Market segmentation breakdown
Prescription-Only Medicines
Over-the-Counter Medicines
By Patient Age Group
Sinusitis Drugs Market segmentation breakdown
Pediatric Patients
Adult Patients
Geriatric Patients
By Distribution Channel
Sinusitis Drugs Market segmentation breakdown
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
By Geography
Sinusitis Drugs Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Sinusitis Drugs Market segmentation breakdown
By Disease Type Acute Sinusitis
Subacute Sinusitis
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
Allergic Fungal Rhinosinusitis
Other Sinusitis Types
By Drug Class Antibiotics
Corticosteroids
Antihistamines
Decongestants
Analgesics & Pain Relievers
Biologic Therapies
Other Drug Classes
By Dosage Form Tablets & Capsules
Nasal Sprays
Nasal Drops
Syrups & Liquids
Injectable Biologics
Other Dosage Forms
By Prescription Status Prescription-Only Medicines
Over-the-Counter Medicines
By Patient Age Group Pediatric Patients
Adult Patients
Geriatric Patients
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is the projected value of the sinusitis drugs market by 2032?

The sinusitis drugs market is forecast to reach USD 3.49 billion by 2032, growing at a 6.99% CAGR from 2027 to 2032.

Which sinusitis drug class is expected to grow fastest?

Biologics is projected to grow at 14.21% CAGR through 2032, supported by treatment use in severe CRSwNP and related inflammatory disease.

Why are biologics becoming more important for chronic rhinosinusitis?

They provide targeted options for eligible patients with severe disease that remain uncontrolled with standard care.

Which dosage form is growing fast for sinusitis treatment?

Injectable biologics are forecast to expand at 13.52% CAGR through 2032, reflecting increasing use in chronic inflammatory disease.

Which region leads to sinusitis drug demand?

North America held a 41.23% share in 2026, supported by specialist access, biologic availability, and insurance coverage.

How are clinical guidelines affecting antibiotic use for sinusitis?

The AAO-HNS guideline supports watchful waiting for uncomplicated acute bacterial rhinosinusitis and limits antibiotic use to appropriate clinical circumstances.

Page last updated on: